Agents already in routine practicebevacizumab, trastuzumab and mirvetuximab soravtansineprovide compelling clinical precedents, while pipeline ADCs and recombinant modulators promise an expanding repertoire of ovary-sparing therapeutics
Journal of Immunotherapy , 47 (9), 369377
You will be able to choose from a selection of matching provider profiles, which will display information including gender, language and specialties
Although the atherosclerotic CV disease risk reduction and CKD progression benefits of SGLT-2 inhibitors may be found to be a class effect in future, the evidence for ertugliflozin (a third SGLT-2 inhibitor recently deleted from the market in Australia) is less robust with further studies ongoing
Dalton M, Buckland N, Blundell J
Mark Hyman I use Empower Pharmacy in my practice because I feel confident in the standards they use, the quality I get, and the results I get with my patients. The Return to Personalized Medicine While the compounding pharmacy has been around for centuries, during the industrialization age, medicines became manufactured and thus more standardized